UNCY Stock Overview
A biotechnology company, develops treatments for various medical conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Unicycive Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.88 |
| 52 Week High | US$1.82 |
| 52 Week Low | US$0.47 |
| Beta | 2.71 |
| 1 Month Change | -21.43% |
| 3 Month Change | -40.94% |
| 1 Year Change | -36.69% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.96% |
Recent News & Updates
Recent updates
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
Feb 16
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 18Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Mar 08Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Sep 07Unicycive Therapeutics GAAP EPS of -$0.24
Aug 16Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Jul 18Shareholder Returns
| UNCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.0% | -0.4% | -0.6% |
| 1Y | -36.7% | 5.5% | 22.2% |
Return vs Industry: UNCY underperformed the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: UNCY underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| UNCY volatility | |
|---|---|
| UNCY Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: UNCY's share price has been volatile over the past 3 months.
Volatility Over Time: UNCY's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 14 | Shalabh Gupta | unicycive.com |
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte.
Unicycive Therapeutics, Inc. Fundamentals Summary
| UNCY fundamental statistics | |
|---|---|
| Market cap | US$33.09m |
| Earnings (TTM) | -US$37.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs UNCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UNCY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$37.82m |
| Earnings | -US$37.81m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did UNCY perform over the long term?
See historical performance and comparison